September 13, 2023
Via: Biopharma DiveAdvisers to the Food and Drug Administration on Wednesday endorsed Alnylam Pharmaceuticals’ drug Onpattro for a rare heart condition, despite questions from agency scientists over the degree of benefit offered by the RNA-based therapy. The advisory committee’s 9-3 vote sets […]
October 28, 2022
Via: PharmaphorumThe IRA was signed by Biden in August and introduced a framework that will require Medicare, the US’s government-run insurance programme for older Americans, to negotiate with manufacturers a “reasonable” price for selected brand name drugs on the basis of […]
January 7, 2022
Via: FierceBiotechAstraZeneca is stepping up its pursuit of a rare disease market targeted by Alnylam and Pfizer. Having entered the ATTR space through its takeover of Alexion, AstraZeneca is paying $30 million for worldwide rights to Neurimmune’s NI006 in its second […]
January 6, 2022
Via: FierceBiotechNovartis is getting back into bed with Alnylam. More than a decade after severing its ties to the RNAi pioneer, Novartis has returned to the deal table for an ambitious early-stage collaboration to restore liver function in patients with end-stage […]
Clinical Trials, FDA, Regulations, Research and Development
October 23, 2020
Via: FierceBiotechAlnylam has shared data from a phase 3 trial of its near-approval kidney disease drug lumasiran in children as young as three months. The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using […]
July 19, 2024
July 11, 2024
July 11, 2024
Copyright © 2024. All rights reserved
